Gossypol

Gossypol

SCHEMBL30260519

Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 12/20 1.00
BCL2 P10415 11/20 1.00
AKR1B1 P15121 5/20 1.00
KDM4E B2RXH2 2/20 1.00
MEN1 O00255 2/20 1.00
NPC1 O15118 2/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
LMNA P02545 2/20 1.00
POLB P06746 2/20 1.00
GAA P10253 2/20 1.00
MAPT P10636 2/20 1.00
THRB P10828 2/20 1.00
HPGD P15428 2/20 1.00
ALOX12 P18054 2/20 1.00
MAPK1 P28482 2/20 1.00
BLM P54132 2/20 1.00
KMT2A Q03164 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gossypol SCHEMBL29798874 1.00 MCL1 (1.00) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL9738017 1.00 MCL1 (1.00) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL3939 1.00 MCL1 (1.00) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL29355719 1.00 MCL1 (1.00) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL23014699 0.98 MCL1 (0.97) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL27542391 0.98 MCL1 (0.97) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL27755741 0.98 MCL1 (0.97) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL28855396 0.98 MCL1 (0.97) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL28166062 0.98 MCL1 (0.97) MCL1BCL2AKR1B1KDM4EMEN1
Gossypol SCHEMBL11156705 0.97 MCL1 (0.94) MCL1BCL2AKR1B1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384171-A1 COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES JANSSEN Pharmaceutica NV (BE) 2024-06-19 EP claimed
WO-2023016995-A1 COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 WO claimed
WO-2025262113-A1 COMBINATION THERAPY USING MALT1 AND BCL-2 INHIBITORS AND METHODS OF REDUCING REGULATORY T CELLS JANSSEN PHARMACEUTICA NV (BE) 2025-12-26 WO disclosed
EP-4384171-A1 COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES JANSSEN Pharmaceutica NV (BE) 2024-06-19 EP disclosed
US-20230074759-A1 METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES JANSSEN PHARMACEUTICA NV (BE) 2023-03-09 US disclosed
WO-2023016995-A1 COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 WO disclosed
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER THE TRUSTEES OF DARTMOUTH COLLEGE 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER MYCBP, MYC, TERF2IP MCL1 103/4885BCL2 854/4885AKR1B1 3517/4885
US-20230074759-A1 METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES MALT1, BCL6, BCL3 MCL1 19/4885BCL2 6/4885AKR1B1 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.